Ultrasound (US) shows subacromial bursitis; what are the next treatment steps?

Treatment of Ultrasound-Confirmed Subacromial Bursitis

Initiate treatment with ultrasound-guided subacromial corticosteroid injection combined with exercise therapy, as this provides superior short-term pain relief and functional improvement compared to conservative management alone.

Initial Treatment Approach

When ultrasound confirms subacromial bursitis, proceed with the following algorithmic approach:

First-Line: Ultrasound-Guided Corticosteroid Injection

Perform ultrasound-guided injection rather than landmark-based injection - this is critical for optimal outcomes. The evidence strongly supports US guidance over palpation-guided techniques, showing significantly better improvements in passive shoulder abduction and quality of life measures 1. US guidance ensures accurate needle placement into the subacromial bursa, which directly correlates with treatment success 2.

Dosing considerations:

• Higher-dose regimen (20 mg triamcinolone) provides more sustained pain relief compared to lower doses (10 mg), with mean pain scores decreasing from 8.1 to 2.4 at six months versus 7.9 to 3.5 with lower doses 3
• Mix corticosteroid with local anesthetic (e.g., 20 mg triamcinolone with 1% lidocaine) 3, 4
• The ACR guidelines explicitly note that ultrasound-guided injection "may include injection of anesthetic and/or corticosteroid if clinically warranted" when bursitis is identified 5

Why Bursitis Presence Matters

The presence of subacromial bursitis on ultrasound is a positive prognostic indicator - patients with documented bursitis show significantly greater improvements in pain (VAS), shoulder function (Constant-Murley Score), disability (SPADI), and range of motion at 3-week follow-up compared to those without bursitis 6, 4. This makes injection therapy particularly appropriate when US confirms bursitis rather than when it's merely suspected clinically.

Specifically, patients with bursal effusion (>2mm) or bursal thickening (>2mm) demonstrate superior response to injection compared to those with normal bursa (<1mm) 4.

Concurrent Conservative Management

Combine injection with exercise therapy - while AAOS guidelines note inconclusive evidence for exercise programs in full-thickness rotator cuff tears 7, the evidence for rotator cuff-related symptoms without full-thickness tears (which includes bursitis) supports exercise and/or NSAIDs as initial nonsurgical treatment 7.

The exercise program should focus on:

• Pain reduction and functional improvement
• Can be supervised or home-based (evidence shows both can be effective) 7
• Continue for at least 8 weeks for optimal benefit

NSAIDs can be used adjunctively for additional anti-inflammatory effect, though evidence is moderate 7.

Follow-Up Timeline

Assess response at:

• 1 week: Expect significant pain reduction and improved passive range of motion 1, 2
• 3 weeks: Peak functional improvement typically observed 6
• 1-3 months: Sustained benefit should be evident; if not, consider re-evaluation 3, 1

When to Consider Re-injection

Secondary injection rates are significantly lower with US-guided technique (13 cases) compared to landmark-guided injection (45 cases) 2. If symptoms recur or persist beyond 1 month:

• Re-evaluate with ultrasound to assess bursal status
• Consider repeat US-guided injection if bursitis persists
• Evaluate for underlying rotator cuff pathology if not previously assessed

Critical Pitfalls to Avoid

1. Don't use landmark-based injection - accuracy matters significantly for outcomes 1, 2
2. Don't underdose corticosteroid - 20 mg triamcinolone provides superior sustained relief compared to 10 mg 3
3. Don't inject without confirming bursitis - presence of bursitis predicts better response 6, 4
4. Don't neglect concurrent exercise therapy - injection alone is suboptimal 7

Alternative/Emerging Options

While corticosteroids remain first-line, emerging evidence suggests:

• Hyaluronic acid may offer alternative for patients with CS contraindications 8
• Platelet-rich plasma (PRP) shows promise but requires more robust evidence 8
• These should be considered second-line or in specific contraindication scenarios

Imaging Considerations

The ACR rates both MRI and ultrasound as "9" (usually appropriate) for evaluating questionable bursitis, noting they are "equivalent in this evaluation" 5. Since you already have US confirmation, no additional imaging is needed unless:

• Symptoms fail to improve after appropriate injection therapy
• Suspicion for full-thickness rotator cuff tear develops
• Need to evaluate for other pathology (biceps tenosynovitis, partial tears)